Everything should be made as simple as possible, but not simpler.
— Albert Einstein
Immuno-oncology therapy, the science of mobilizing the immune system to kill cancer, has been pursued for more than a century. Recently this powerful approach has taken the center stage in cancer therapies. Ipilimumab and nivolumab/pembrolizumab are among the earliest immune checkpoint inhibitors (targeting CTLA-4 and PD-1, respectively) and have transformed the therapeutic approach as new and promising tools for cancer management.
To effectively kill cancer cells using the immune system, a complete Cancer-Immunity Cycle (Chen & Mellman, 2013) including a series of stepwise events must be initiated and allowed to proceed and expand iteratively. Each step of the Cancer-Immunity Cycle requires the coordination of numerous stimulatory and inhibitory factors in nature.
There are two major constraints in advancing new cancer immunotherapies: differentiated biology in the lab that will faithfully translate into clinical benefits, and a working system to quickly prove the benefits in clinical settings.
At Elpiscience, we are focused on biological insights. We endeavor to find differentiated biology in a complex immune system in order to effectively eradicate tumors. Elpiscience is fortunate to have science-driven talents searching for answers in the lab, world-renowned experts guiding our scientific strategies, and global collaborators sharing a common vision in the power of translational science to help patients.